This A673T mutation results in an approximately 40% reduction in the formation of amyloidegenic peptides in vitro and provides proof of principle for the hypothesis that reducing the amyloidogenic cleavage of APP may protect against AD (Jonsson et al., 2012). The gene discussed is APP; the disease is Alzheimer disease.